Faeth Therapeutics, Inc. Finance Lease, Right-of-Use Asset, Amortization
Faeth Therapeutics, Inc. (FTH) reported Finance Lease, Right-of-Use Asset, Amortization of $1.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-04
- Faeth Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Faeth Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $1.00K, a 75.00% decline year-over-year.
- Faeth Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $4.00K, a 97.92% decline year-over-year.
- Faeth Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $4.00K, a 97.92% decline year-over-year.
- Faeth Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2025 was $17.00K, a 97.80% decline from fiscal 2024.
- Faeth Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2024 was $771.00K, a 1.15% decline from fiscal 2023.
- Faeth Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2023 was $780.00K, a 6.41% increase from fiscal 2022.
- Faeth Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2022 was $733.00K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.00K 10-Q · filed 2026-08-04 | $5.00K derived: sum of 3 quarters · filed 2026-08-04 | $9.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $1.00K 10-Q · filed 2026-05-15 | $5.00K derived: sum of 2 quarters · filed 2026-05-15 | $9.00K derived: sum of 3 quarters · filed 2026-05-15 | $14.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $8.00K derived: sum of 2 quarters · filed 2026-03-30 | $13.00K derived: sum of 3 quarters · filed 2026-08-04 | $17.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $9.00K derived: sum of 2 quarters · filed 2026-08-04 | $13.00K 10-Q · filed 2025-11-14 | $205.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $9.00K 10-Q · filed 2026-08-04 | $201.00K derived: sum of 3 quarters · filed 2026-08-04 | $393.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $4.00K 10-Q · filed 2026-05-15 | $196.00K derived: sum of 2 quarters · filed 2026-05-15 | $388.00K derived: sum of 3 quarters · filed 2026-05-15 | $581.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $192.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $384.00K derived: sum of 2 quarters · filed 2026-03-30 | $577.00K derived: sum of 3 quarters · filed 2026-03-30 | $771.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $192.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $385.00K derived: sum of 2 quarters · filed 2025-11-14 | $579.00K 10-Q · filed 2025-11-14 | $773.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $193.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $387.00K 10-Q · filed 2025-08-05 | $581.00K derived: sum of 3 quarters · filed 2025-08-05 | $776.00K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $194.00K 10-Q · filed 2025-05-06 | $388.00K derived: sum of 2 quarters · filed 2025-05-06 | $583.00K derived: sum of 3 quarters · filed 2025-05-06 | $777.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $389.00K derived: sum of 2 quarters · filed 2025-03-28 | $583.00K derived: sum of 3 quarters · filed 2025-03-28 | $780.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $195.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $389.00K derived: sum of 2 quarters · filed 2024-11-14 | $586.00K 10-Q · filed 2024-11-14 | $775.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $194.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $391.00K 10-Q · filed 2024-08-06 | $580.00K derived: sum of 3 quarters · filed 2024-08-06 | $771.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $197.00K 10-Q · filed 2024-05-09 | $386.00K derived: sum of 2 quarters · filed 2024-05-09 | $577.00K derived: sum of 3 quarters · filed 2024-05-09 | $753.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $189.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $380.00K derived: sum of 2 quarters · filed 2024-02-29 | $556.00K derived: sum of 3 quarters · filed 2024-02-29 | $733.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $191.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $367.00K derived: sum of 2 quarters · filed 2023-11-07 | $544.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $176.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $353.00K 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $177.00K 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |